Evidence map›Paper›PMID 42811101›Full record

ReviewNature reviews. Drug discovery2026

The cellular landscape of druggable RNA-binding proteins.

Gaia Di Timoteo, Benson M George, Omar Abdel-Wahab, Ryan A Flynn, Konstantinos Tzelepis

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gaia Di TimoteoCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Benson M GeorgeStem Cell and Regenerative Biology Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Omar Abdel-WahabMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. abdelwao@mskcc.org.ORCID http://orcid.org/0000-0002-3907-6171
Ryan A FlynnStem Cell and Regenerative Biology Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA. Ryan.Flynn@childrens.harvard.edu.ORCID http://orcid.org/0000-0001-5013-0442
Konstantinos TzelepisCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk.ORCID http://orcid.org/0000-0002-4865-7648

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA-binding proteins (RBPs) are involved in every step of RNA metabolism, from RNA processing and modification to translation and decay, and are also important for the function of non-coding RNAs. As such, RBPs are crucial in shaping cell identity and are central to the development of numerous diseases. Over the past decade, systematic efforts to explore the RNA interactome have expanded the RBP census as well as the landscape of potentially therapeutically targetable RBPs. More recently, certain RBPs have been shown to be present on the cell surface with cell-type and disease-associated specificities. These cell surface RBPs could potentially serve as biomarkers and immunotherapy targets in a variety of diseases. Here, we summarize established intracellular roles for RBPs, as well as their connections to disease with an emphasis on cancer. Moreover, we review the nascent field of cell surface RBPs and describe strategies to harness the cell surface localization of RBPs for the design and development of novel immunotherapeutic modalities.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.